Enalapril
Clinical data | |
---|---|
Trade names | Vasotec, Renitec, Enacard, others |
AHFS/Drugs.com | Monograph |
MedlinePlus | a686022 |
License data | |
Pregnancy category | |
By mouth | |
Drug class | ACE inhibitor |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 60% (by mouth) |
Metabolism | Liver (to enalaprilat) |
Elimination half-life | 11 hours (enalaprilat) |
Excretion | Kidney |
Identifiers | |
| |
JSmol) | |
Melting point | 143 to 144.5 °C (289.4 to 292.1 °F) |
| |
| |
(verify) |
Enalapril, sold under the brand name Vasotec among others, is an
Common side effects include
Enalapril was patented in 1978, and came into medical use in 1984.
Medical uses
Enalapril is used to treat hypertension, symptomatic heart failure, and asymptomatic left ventricular dysfunction.
Side effects
The most common side effects of enalapril include increased
Some evidence suggests enalapril will cause injury and death to a developing fetus. In pregnancy, enalapril may result in damage to the fetus's kidneys and resulting oligohydramnios (not enough amniotic fluid). Enalapril is secreted in breast milk and is not recommended for use while breastfeeding.[3]
Mechanism of action
Normally,
Pharmacokinetics
Pharmacokinetic data of enalapril:[3]
- Onset of action: about 1 hour
- Peak effect: 4–6 hours
- Duration: 12–24 hours
- Absorption: ~60%
- Metabolism: prodrug, undergoes biotransformation to enalaprilat[20]
Structure activity relationship
Enalapril has an L-proline moiety as a part of the molecule which is responsible for the oral bioavailability of the drug. It is a pro-drug, which means that it exerts its function after being metabolized. The "-OCH2CH3" part of the molecule will split during the metabolism and at the carbon will be a carboxylate, which then interacts with the Zn+2 site of the ACE enzyme. This structural feature and mechanism of metabolism that must occur before the drug can inhibit the enzyme explains why it has a greater duration of action than another similar drug used for the same indication, Captopril. Duration of effect is dose-related; at recommended doses, antihypertensive and haemodynamic effects have been shown to be maintained for at least 24 hours.[21][22] Enalapril has a slower onset of action than Captopril but a greater duration of action. However, unlike Captopril, Enalapril does not have a thiol moiety.
History
Squibb developed the first ACE inhibitor,
: 12–13Enalaprilat was developed first, partly to overcome these limitations of captopril. The sulfhydryl moiety was replaced by a carboxylate moiety, but additional modifications were required in its structure-based design to achieve a potency similar to captopril. Enalaprilat, however, had a problem of its own in that it had poor oral availability. This was overcome by the Merck researchers through the esterification of enalaprilat with ethanol to produce enalapril.[24]
Merck introduced enalapril to market in 1981; it became Merck's first billion dollar-selling drug in 1988.[24] The patent expired in 2000, opening the way for generics.[25]
Society and culture
Legal status
In September 2023, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion, recommending the granting of a pediatric use marketing authorization for the medicinal product Aqumeldi, intended for the treatment of heart failure in children from birth to less than 18 years of age.[26] The applicant for this medicinal product is Proveca Pharma Limited.[26] Aqumeldi was approved for medical use in the European Union in November 2023.[4]
References
- ^ a b "Enalapril Use During Pregnancy". Drugs.com. 28 February 2020. Retrieved 13 March 2020.
- FDA. Retrieved 22 October 2023.
- ^ a b c d e f "Vasotec- enalapril maleate tablet". DailyMed. 12 November 2018. Retrieved 26 April 2020.
- ^ a b "Aqumeldi EPAR". European Medicines Agency. 15 November 2023. Retrieved 20 January 2024. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ a b c d e f g "Enalaprilat/Enalapril Maleate". The American Society of Health-System Pharmacists. Archived from the original on 21 December 2016. Retrieved 8 December 2016.
- ISBN 9789241547659.
- ISBN 9783527607495. Archivedfrom the original on 20 December 2016.
- hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
- ^ "The Top 300 of 2021". ClinCalc. Archived from the original on 15 January 2024. Retrieved 14 January 2024.
- ^ "Enalapril - Drug Usage Statistics". ClinCalc. Retrieved 14 January 2024.
- ^ "Enalapril maleate: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 24 September 2021.
- ^ "Enalapril". MedlinePlus. U.S. National Library of Medicine. October 2010. Archived from the original on 8 February 2015.
- ^ PMID 26597926.
- PMID 26868137.
- S2CID 96434746.
- PMID 20089973.
Two large trials showed that when patients with NYHA class II, III, or IV heart failure were treated with enalapril, as compared with placebo, in addition to diuretics and digoxin, the rates of admission to the hospital were reduced, and the relative risk reduction for death was 16 to 40%.
- S2CID 31791094.
- PMID 9509495.
- S2CID 262278681.
- ^ "Enalapril 10mg Tablets - Summary of Product Characteristics. Section 5.1 Pharmacodynamic properties". emc (electronic medicines compendium). 21 February 2023.
- PMID 6202969.
- ^ Bryan J (April 2009). "From snake venom to ACE inhibitor--The discovery and rise of captopril". Pharmaceutical Journal. 282 (7548): 455.
- ^ ISBN 9781118354469.
- ^ Staff, Drug Discovery Online. Patent expiry looms: 18 blockbusters expose $37 billion to generic competition by 2005 Archived 12 May 2016 at the Wayback Machine Page accessed 23 April 2016
- ^ a b "Aqumeldi: Pending EC decision". European Medicines Agency. 15 September 2023. Retrieved 21 September 2023. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.